MedPath

Adherence therapy for schizophrenia

Completed
Conditions
Schizophrenia
Mental and Behavioural Disorders
Registration Number
ISRCTN76324634
Lead Sponsor
Clinic of Psychiatry and Psychotherapy Bethel (Germany)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
160
Inclusion Criteria

1. Patients between 18 and 65 years old
2. Patients with schizophrenia will be enrolled when the initial acute psychotic symptoms are reduced (partial remission) from a clinical point of view so that they were able to provide a written informed consent
3. Clinical diagnosis of schizophrenia will be confirmed by a research diagnosis of schizophrenia, established using the International Diagnostic Checklist for ICD-10
4. Patients will be taking antipsychotic medication at the time of recruitment, and the current treating psychiatrist has recommended the individual patient to stay on antipsychotic medication for a minimum of one year.

Exclusion Criteria

1. Potential study participants will be excluded if they show acute suicidal behaviours including suicidal ideas
2. Insufficient German language capacities
3. Are administered depot medication
4. Are homeless, or suffered from a current substance or alcohol dependence (not caffeine or nicotine dependence) or mental retardation according to International Classification of Diseases (ICD-10) and Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria.
5. Patients are under compulsory treatment, if they are homeless or suffer from severe medical conditions (eg. cancer, severe infection)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Adherence - determined using drug serum levels (concentration to dose ratio)<br>2. Symptoms - measured using the postive and negative syndrome scale<br><br>Measured at baseline and 26 week follow-up
Secondary Outcome Measures
NameTimeMethod
1. Attitudes to treatment - assessed using the drug attitude inventory<br>2. Functioning - determined using the global assessment of functioning<br><br>Measured at baseline and 26 week follow-up
© Copyright 2025. All Rights Reserved by MedPath